Spotlight: UK and Ireland
Dealmaking conditions tightened notably in Q3, as borne out in our latest heatmap analysis.
Read moreWe work closely with entrepreneurs and investors at the forefront of the global healthcare revolution. Our in-depth sector knowledge, combined with our technical capability, enables us to help corporates and investors capitalise on the enormous opportunities across the sector as they seek to consolidate and grow their market positions.
The ageing population, technological change, and increased demand for healthcare products and services, all create great opportunities in the health and social care, medical devices, life sciences, bioscience and pharmaceutical markets. Our job is to help our clients maximise those opportunities.
Luc Bertholat, Partner, Naxicap PartnersClearwater has been very professional in leading the process involving candidates from all over the world.
The team were quickly able to identify the right partner for us and used their excellent relationship with the buyer to help negotiate a transaction that met our objectives.Dan Smart, CEO, Proclinical
With in-depth knowledge and technical capability, our healthcare team has a great track record of delivering tailored solutions.
See our teamOver 85
deals advised upon
in the last 5 years
€14.5bn
deal value
over the last 5 years
Over 55%
deals involving PE
in the last 5 years
Dealmaking conditions tightened notably in Q3, as borne out in our latest heatmap analysis.
Read moreFollowing the publication of the Q1 2022 Clearwater International Multiples Heatmap, Mergermarket interviewed Clearwater’s executive team to discuss trends driving deal activity in healthcare.
Read morePE deals accounted for one-third of all Q1 M&A transactions in 2022, one of the highest proportions on record. Our latest Multiples Heatmap report explores the major themes driving EV/EBITDA multiples in European PE deals with the goal to assist PE investors with their strategic decisions.
Read more